|
Diurnal Group PLC on Wednesday announced a distribution agreement for Alkindi with Vector Pharma, a full-service distribution provider.
Under the agreement, Vector Pharma will receive exclusive rights to distribute Alkindi to 14 countries in the Middle East and North Africa from the second quarter of 2022.
Alkindi is a preparation of hydrocortisone designed for use in children suffering from paediatric adrenal insufficiency, a condition in which the adrenal glands do not produce enough of the hormone cortisol. The preparation supplies the cortisol as a medication.
The preparation will be available to paediatric patients who qualify through applicable early access programmes for patients with diseases of cortisol deficiency who have no other treatment options.
Alkandi is already approved in the UK, the European Economic Area, Israel, Australia and the US, Diurnal, a Cardiff, Wales-based pharmaceutical company focused on hormonal diseases added.
‘We are pleased to be working with Vector Pharma to extend the availability of Alkindi to a large geographic region where there is a significant unmet patient need in children suffering from AI and CAH. Working with Vector Pharma will further broaden the future availability of Alkindi outside of our core markets and we believe that Vector Pharma is well-positioned to distribute Alkindi across the 14 counties in this agreement and to ensure it reaches key healthcare providers and patients,’ said Chief Executive Officer Martin Whitaker.
Diurnal shares were 3.8% lower at 15.30 pence each in London on Wednesday afternoon.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
